Ignite Creation Date:
2025-12-25 @ 2:17 AM
Ignite Modification Date:
2026-03-01 @ 10:01 AM
Study NCT ID:
NCT01902160
Status:
COMPLETED
Last Update Posted:
2015-11-09
First Post:
2013-07-15
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Sponsor:
National Cancer Institute (NCI)
Organization:
Organization Data
Organization:
Class:
NIH
Study ID:
NCI-2013-01273
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
NIH
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None